News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis from EASE LID 2 Open-label Study

(February 8, 2018) - Adamas Pharmaceuticals, Inc. announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate release (IR) who were still experiencing dyskinesia and enrolled into EASE LID 2, the long-term, ongoing Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, were published online in Movement Disorders Clinical Practice. Results from the subgroup analysis showed that the 32 Parkinson’s disease patients who were taking amantadine IR at enrollment experienced a 35 percent improvement in motor complications at Week 8, the first post-baseline visit, after transitioning directly to GOCOVRI, without exacerbating adverse events. Read more